Efficacy of LORVIQUA as a First Line Agent in ALK+ Advanced NSCLCLORVIQUA significantly improved progression-free survival vs crizotinib1,2 Progression-free survival by BICR (ITT population, N=296)1,2

Data cutoff: 20 March 2020.2

  • Patients receiving LORVIQUA experienced longer PFS vs crizotinib, irrespective of baseline patient and disease characteristics1,2
  • At data cutoff, OS data were not mature2
Progression-free survival (BICR assessed): subgroup analysis4

Data cutoff: 20 March 2020.2
Adapted from: Supplement to Shaw AT, Bauer TM, de Marinis F, et al; CROWN Trial Investigators.
First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):
2018-2029. 

This graph depicts prespecified exploratory subgroup analyses from the CROWN trial. Small patient numbers can be a limitation of subgroup analyses. These results are presented for descriptive purposes and should not be interpreted as a demonstration of efficacy in any particular subgroup.

Improved tumour response with LORVIQUA vs crizotinib1,2 ORR (ITT population, N=296)a

aDefined as confirmed complete response or partial response as assessed by BICR.1,2 
Data cutoff: 20 March 2020.2

  • Median DoR: Not estimable (95% Cl, NE-NE) with LORVIQUA vs 11 months (95% Cl, 9-13) with crizotinib1,2
  • Response duration ≥12 months: 70% with LORVIQUA vs 27% with crizotinib3
BICR=blinded independent central review; CNS=central nervous system; DoR=duration of response; ECOG PS=Eastern Cooperative Oncology Group performance status; HR=hazard ratio; ITT=intention to treat; NE=not estimable; ORR=objective response rate; OS=overall survival; PFS=progression-free survival.ReferencesReferences:

1. Pfizer. LORVIQUA (lorlatinib) Summary of Product Characteristics. 

2. Solomon, Bauer at al; Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir Med 2023;11: 354–663. Shaw AT, Bauer TM, de Marinis F, et al; CROWN Trial Investigators. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018-2029.
4. Shaw AT, Bauer TM, de Marinis F, et al; CROWN Trial Investigators. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. [supplementary appendix]N Engl J Med. 2020;383(21):2018-2029.
Efficacy
LORVIQUA safety profile
 Review the safety
PP-LOR-IRL-0068 February 2024 Legal Category S1A Further Information Available on Request
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0784. June 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


PP-UNP-IRL-0784. June 2024